MAPK3 and head and neck squamous cell carcinoma: Since ERK1/2 is a major switch between proliferation and EMT induction in HNSCC [88] and ERK2 is upregulated in recurrent tumors [97], a specific targeting of ERK signaling may represent a druggable option.